Introduction
Prolactinomas are the most frequently encountered hormone-secreting pituitary neoplasms and constitute 40% of all pituitary adenomas. 1 Despite being histologically benign, prolactinomas often invade surrounding structures including the cavernous sinus, the sphenoid sinus and the diaphragma sellae. 2 This capacity for aggressive local growth not only makes complete surgical excision difficult but also imposes significant neurological and endocrinological morbidity. 3 Mechanisms underlying the aggressive biological behaviour of prolactinomas have not been fully clarified. 4 Angiogenesis, which describes the formation of neovasculature from the existing vascular system, is a key step for tumour progression and invasion. Angiogenesis is correlated with the development of metastasis, poor prognosis, lower survival and higher recurrence in M Jiang, CZ Mou, T Han et al. TSP-1 and TGF-b 1 in prolactinoma many human tumours, including breast, bladder and stomach cancers. 5, 6 Increased angiogenesis, as assessed by microvessel density, has been shown to be associated with aggressive behaviour in different tumour types, 7, 8 but this relationship is less clear in pituitary tumours. Some research has found reduced microvessel density in pituitary adenomas compared with normal pituitary tissue, 9 whereas others have reported higher microvessel density in invasive pituitary adenomas compared with noninvasive tumours. 10 A further study found no significant correlation between microvessel density and tumour invasiveness. Thrombospondin-1 (TSP-1) is a 450 kDa extracellular matrix glycoprotein that is produced by platelets, endothelial cells, fibroblasts, monocytes and macrophages, which has multiple functions including platelet-monocyte linking, tumour cellendothelial cell attachment and apoptosis of endothelial cells. 12 -17 TSP-1 has been shown to act as an inhibitor of angiogenesis and tumour progression 18 but, to our knowledge, there have been no reports on the associations between TSP-1 and angiogenesis or invasiveness in prolactinomas.
Transforming growth factor-β 1 (TGF-β 1 ) is a multifunctional cytokine that regulates cell proliferation, differentiation and production of extracellular matrix. 19 TGF-β has been shown to both inhibit and stimulate tumour progression, depending on the level of TGF-β activity, TGF-β receptor status and tumour stage. 20 TSP-1 is an activator of TGF-β, 21 and the increased production of TSP-1 in glioma has been shown to increase malignancy by generating active TGF-β in tumour tissue. 22 In contrast, stromal expression of TSP-1 in colorectal cancer inhibited angiogenesis and tumour growth by activating TGF-β 1 . 23 The relationships between TSP-1, TGF-β and tumour growth need to be investigated further in a variety of tumour types. The present study investigated: (i) the value of microvessel density as a predictor of invasiveness in pituitary adenoma; (ii) TSP-1 and TGF-β 1 protein in invasive and noninvasive prolactinomas; and (iii) the relationship between microvessel density, TSP-1 and TGF-β 1 , and the clinicopathological features of prolactinoma. 
Patients and methods

STUDY POPULATION
TUMOUR DEFINITIONS
Tumour size and invasiveness were defined on the basis of preoperative radiological investigations and surgical findings, using a modified Hardy's classification. 24 Grade I (microadenomas, < 1 cm in diameter) and grade II tumours (enclosed macroadenomas with or without suprasellar extension, ≥ 1 cm in diameter) were defined as noninvasive. Grade III (local invasion of sphenoid and/or cavernous sinus) and grade IV tumours (with central nervous system/extracranial spread, with or without metastases) were considered to be invasive. 
TISSUE SAMPLE PREPARATION
Tissue samples for Western blotting were snap frozen in liquid nitrogen immediately after surgical resection and stored at −80°C until use. Tissue samples for immunohistochemistry were fixed in 4% buffered formalin, dehydrated and embedded in paraffin.
IMMUNOHISTOCHEMISTRY
Formalin fixed, paraffin-embedded tissue samples were cut into sections (4 µm thick), deparaffinized in xylene, and rehydrated through a series of graded alcohols. For antigen retrieval, sections were boiled in 0.01 M citrate buffer (pH 6.0) in a microwave oven for 20 min. Endogenous peroxidase activity was blocked by treatment with 3% hydrogen peroxide for 30 min at room temperature, followed by incubation in 5% goat serum for 60 min at room temperature, to prevent nonspecific antigen binding. Slides were then incubated with the following primary antibodies overnight at 4°C: monoclonal mouse antihuman TSP-1 (1 : 100 dilution; Calbiochem-Novabiochem [EMD Chemicals], San Diego, CA, USA); polyclonal rabbit antihuman TGF-β 1 (1 : 100 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA); and monoclonal mouse antihuman CD34 (1 : 100 dilution; Maixin-Bio, Fuzhou, China). Slides were washed three times with 0.01 M phosphate buffered saline (PBS; pH 7.4) and incubated with biotinylated goat antimouse/goat antirabbit immuno globulin G (1 : 200 dilution; Zhongshan, Bejing, China) at room temperature for 30 min. Slides were washed three times with PBS, then incubated with peroxidase-conjugated streptavidin (Zhongshan) at room temperature for 30 min. After final washing, the chromogenic reaction was developed with diamino benzidine (Zhongshan). Positive and negative controls (as recommended by the antibody manufacturers) were included in each run. Slides were counterstained lightly with haematoxylin, mounted and observed under a light microscope by two experienced pathologists who were blinded to the clinical data.
EVALUATION OF IMMUNOSTAINING
Immunostaining for TSP-1 was classified according to the percentage of stained cells and their intensity, by counting 100 cells/field (magnification × 400) in five fields for each slide and three slides for each tissue sample. Staining intensity was scored as 0 (negative), 1 (weak), 2 (moderate) or 3 (strong); extent of staining was scored as 0 (0%), 1 (1 -30%), 2 (30 -70%) or 3 (71 -100%) of the entire tumour area. The final staining score was the mean of the sum of the intensity and extent scores. Scores ≥ 3 were considered positive and scores < 3 were considered negative. TGF-β 1 staining was considered positive when ≥ 10% of the tumour cells were stained, as described previously. 25 Microvessel density was determined via CD34 staining, as described previously. 26 Briefly, microvessels were counted at × 200 magnification in the three most vascularized areas of the tumour and a mean value was calculated. Any brownstained endothelial cell or cluster that was separate from other nearby microvessels was counted, with glomeruloid clusters counted as one microvessel. The presence of a vascular lumen was not necessary to identify a microvessel. The overall mean microvessel density of all tumours was used to define low and high microvessel density.
WESTERN BLOTTING
Total protein was extracted from frozen M Jiang, CZ Mou, T Han et al. TSP-1 and TGF-b 1 in prolactinoma tumour tissue (0.5 g) using protein extraction reagent (Beyotime Biotech, Jiangsu, China) according to the manufacturer's instructions, and quantified using a bicinchoninic acid protein assay kit (Beyotime Biotech). Total protein (50 µg from each sample) was subjected to 10% sodium dodecyl sulphatepolyacrylamide gel electrophoresis at 160 mA for 90 min, and transferred to a nitrocellulose membrane (Sigma-Aldrich, St Louis, MO, USA) using an electrophoretic transfer cell (Bio-Rad, Richmond, CA, USA) at 150 mA for 1 h. Membranes were blocked with Tris-buffered saline/Tween-20 (TBST; 20 mM Tris, 0.05% Tween-20, 150 mM sodium chloride; pH 7.4) containing 5% skimmed milk powder for 1 h at room temperature, followed by incubation in TBST containing 5% bovine serum albumin (Sigma-Aldrich) and primary antibodies overnight at 4°C. Primary antibodies were: monoclonal mouse antihuman TSP-1 (1 : 1000 dilution; Calbiochem-Novabiochem [EMD Chemicals]); polyclonal rabbit antihuman TGF-β 1 (1 : 2000 dilution; Santa Cruz Biotechnology); and rabbit antihuman β-actin (internal control; 1 : 1000 dilution; Santa Cruz Biotechnology). Membranes were washed three times with TBST at room temperature for 10 min, incubated with horseradish peroxidase-conjugated goat antimouse/antirabbit immunoglobulin G (1 : 2000 dilution; Zhongshan) at room temperature for 2 h, and washed three times with TBST. Proteins were detected using an EZ-ECL chemiluminescence detection kit for horseradish peroxidase (Biological Industries, Kibbutz Beit-Haemek, Israel) and analysed with Multi Gauge software, version 3.2 (Fujifilm Medical Systems USA, Stamford, CT, USA). Table 1 .
STATISTICAL ANALYSES
A representative light photomicrograph of the CD34 immunohistochemical staining that was used to assess microvessel density is shown in Fig. 1 . The overall mean microvessel density (used to define high or low microvessel density) was 28.043 ± 0.796 microvessels/field (× 200 magnification). Microvessel density was significantly higher in invasive prolactinomas than in noninvasive tumours (34.847 ± 0.843 versus 25.042 ± 0.432 microvessels/field; P < 0.05). Significantly more macroadenomas (≥ 1 cm diameter) than microadenomas (< 1 cm diameter) were classified as having high microvessel density (P = 0.007; Table 1 ). There were no significant differences in microvessel density when patients were stratified according to age (< or ≥ 50 years) or gender (Table 1) .
Immunostaining for TSP-1 was present in M Jiang, CZ Mou, T Han et al. (Fig. 2) . Significantly more noninvasive prolactinomas were classified as TSP-1-positive than invasive tumours (P = 0.01; Table 1 ), and TSP-1 protein levels were significantly lower in invasive tumours than in noninvasive tumours (P < 0.05; Fig 3) . TSP-1-positive tumours were significantly more likely to be microadenomas than macroadenomas (P = 0.001; Table 1 ). There 
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were no significant associations between TSP-1-positivity and patient age or gender (Table 1) .
Immunohistochemical analyses identified TGF-β 1 protein in the cytoplasm of tumour cells (Fig. 4) . Microadenomas were significantly more likely to be TGF-β 1 -negative than macroadenomas (P = 0.028; Table 1 ). Invasive prolactinomas were significantly more likely to be TGF-β 1 -positive than noninvasive tumours (P = 0.002; Table 1 ), and TGF-β 1 protein levels FIGURE 3: Levels of thrombospondin-1 (TSP-1) and transforming growth factor β 1 (TGF-β 1 ) protein in noninvasive and invasive prolactinomas, quantified relative to β-actin protein levels in Western blotting. *P < 0.05 versus noninvasive tumours; Student's t-test were significantly higher in invasive tumours than in noninvasive tumours (P < 0.05; Fig. 3 ). There was no relationship between TGF-β 1 -positivity and patient age or gender ( Table 1) .
The mean microvessel density in TSP-1-positive prolactinomas was significantly lower than that in TSP-1-negative prolactinomas (16.625 ± 0.363 vs 31.543 ± 0.462 microvessels/field, P < 0.05). The mean microvessel density in TGF-β 1 -positive prolactinomas was significantly higher than that in TGF-β 1 -negative prolactinomas (30.542 ± 0.463 vs 20.424 ± 0.173 microvessels/field, P < 0.05). Of the 19 TSP-1-positive prolactinomas, five (26.3%) were positive for TGF-β 1 , and 52/62 (83.9%) of TSP-1-negative prolactinomas were positive for TGF-β 1 . TSP-1-immunopositivity was inversely correlated with TGF-β 1 -immunopositivity (r s -1.0, P < 0.01).
Discussion
Angiogenesis is a rate-limiting step in tumour growth and invasion, 27 but its role in the progression of pituitary adenomas is unclear. Increased microvessel density was associated with prolactinoma invasiveness and large tumour size in the present study, but there was no association with patient age or gender. Angiogenesis may, therefore, play an important role in the development and progression of prolactinoma. Microvessel density has been studied in many neoplasms. 26 Research in nonsmallcell lung cancer found a relationship between microvessel density and tumour progression, treatment response and outcome. 28 A higher microvessel density is often associated with a greater invasive ability of the tumour. 26 In contrast to other tumour types that are more vascularized than their adjacent normal tissues, 28, 29 the microvessel density of pituitary adenomas was found to be lower than that of normal pituitary glands. 30 In addition, vascularity in pituitary carcinomas is not increased when compared with adenomatous or normal pituitary tissue, 31 which may partly explain why pituitary neoplasms are benign and slow growing. In contrast with many other solid tumours, in which angiogenesis drives the malignancy, the invasiveness of pituitary adenomas does not always correlate with the extent of angiogenesis. 32 A significant difference in microvessel density between invasive and noninvasive prolactinoma was demonstrated in the present study, however. These findings are in accordance with others, 10 but a similar correlation has not been found in growth hormone or adrenocorticotropic hormone tumour subgroups, 32 suggesting a difference in the neovascularization regulatory mechanism based on histological type. These inconsistencies may be due to the different proportions of pituitary adenoma subtypes included in the different reports. The current study found no difference in microvessel density based on patient gender or age, in line with a report in pituitary adenomas. 33 Our findings, therefore, suggest that microvessel density is associated with the invasiveness of prolactinoma, but more investigations are required in other pituitary adenoma subtypes. In addition to the gross quantification of new blood vessels, the present study investigated the role of TSP-1 and TGF-β 1 in prolactinoma progression, and found that both were related to tumour angiogenesis and invasiveness. TSP-1 was the first endogenous protein inhibitor of angiogenesis to be identified 34 and research has found that the effect of TSP-1 on angiogenesis varies according to the tumour microenvironment. 35 The binding of TSP-1 to its receptor CD36 inhibits adhesion, proliferation and tube formation of endothelial cells, leading to the M Jiang, CZ Mou, T Han et al. TSP-1 and TGF-b 1 in prolactinoma inhibition of angiogenesis. 36 The inhibition of angiogenesis by TSP-1 antisense RNA and the promotion of vascular endothelial apoptosis by recombinant TSP-1 have been reported. 37, 38 Although the majority of studies indicate that TSP-1 has an angiogenesis-inhibiting effect, it has also been shown to promote angiogenesis by stimulating growth and migration of myofibroblasts 39 and promoting vascular endothelial growth factor (VEGF) production. 25 To our knowledge, the relationship between TSP-1 and angiogenesis in pituitary adenomas has not been previously examined. The presence of TSP-1 was inversely associated with microvessel density in the current study, suggesting that TSP-1 functions as an angiogenesis inhibitor in prolactinoma. In addition, in the present study, a significantly higher proportion of noninvasive prolactinomas than invasive prolactinomas was TSP-1-positive, suggesting that TSP-1 may inhibit tumour progression via an antiangiogenic effect. There is evidence to suggest that TSP-1 activates TGF-β 1 in the tumour microenvironment. 40 It is thought that TSP-1 inhibits tumour growth not only by inhibiting angiogenesis but also by inhibiting tumour cell proliferation through activation of TGF-β. 40 TSP-1 immunopositivity was inversely correlated with TGF-β 1 immunopositivity in the present study, suggesting that the inhibitory activity of TSP-1 was not related to the activation of TGF-β 1 .
Transforming growth factor-β 1 is a multifunctional cytokine, which is converted to a biologically active form by TSP-1 in order to function as a tumour growth regulator. 41 TGF-β 1 is a potent inducer of growth inhibition and cell apoptosis in several cell types, 42 but may also act as a proangiogenic factor. 43 TGF-β 1 is the major modifier of vascular smooth muscle cell proliferation and motility, both of which are critical for microvasculature stability. 42 TGF-β 1 also stimulates the production of VEGF, which is a major promoter of angiogenesis. 43 In addition, TGF-β 1 produced by tumour cells and stromal cells accumulates in tumour tissue, facilitates the development of stromal tissues and plays a crucial role in tumour extension. 44 The mechanisms supporting TGF-β-mediated tumour growth and angiogenesis are, therefore, complex and may vary with tumour type. In prolactinoma, the relationship between invasiveness and TGF-β 1 remains unclear. A significant positive association was found between TGF-β 1 -positivity and microvessel density in the present study, and this finding was consistent with other research. 45 In addition, a positive association was found between TGF-β 1 protein levels and prolactinoma invasiveness in the present study. The results of the current study suggest that excessive TGF-β 1 production may play a role in angiogenesis, and also in the pathogenesis of prolactinomas, and that this could lead to enhanced tumour invasiveness.
In conclusion, microvessel density may be a predictor of invasiveness in prolactinoma. The current findings suggest that TSP-1 suppresses prolactinoma invasion by inhibiting angiogenesis, and that TGF-β 1 promotes invasion by facilitating angiogenesis. TSP-1 and TGF-β 1 are likely to be useful molecular tools for the diagnosis and prognosis of invasive prolactinoma, and may be effective targets for gene therapy.
